Your browser doesn't support javascript.
loading
Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report.
Matsunuma, Ryoichi; Sato, Shoko; Chan, Jason Yongsheng; Kinoshita, Kazuo; Taku, Keisei; Yamaguchi, Kei; Hayami, Ryosuke; Arai, Kazumori; Suzuki, Makoto; Tsuneizumi, Michiko.
Afiliação
  • Matsunuma R; Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Sato S; Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Chan JY; Division of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
  • Kinoshita K; Evolutionary Medicine, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
  • Taku K; Division of Medical Oncology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Yamaguchi K; Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Hayami R; Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Arai K; Department of Pathology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Suzuki M; Department of Pathology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
  • Tsuneizumi M; Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan.
Case Rep Oncol ; 16(1): 455-464, 2023.
Article em En | MEDLINE | ID: mdl-37497424
ABSTRACT
Primary breast angiosarcoma is an extremely rare disease with a poor prognosis. Primary angiosarcoma is distinct from secondary angiosarcoma, which usually occurs in patients who have been previously treated for breast cancer. The low incidence of primary breast angiosarcoma has hindered the elucidation of its etiology and potential therapies. Here, we report a case of a patient with primary breast angiosarcoma who experienced recurrence after surgery. The tumor was refractory to systemic treatments, and the patient died 18 months after the surgery. We used RNA sequencing for gene expression profiling of the tumor. A high tumor inflammation signature score indicated enrichment in immune-related signaling. CIBERSORTx, a tool used to characterize the cellular composition of complex tissues based on gene expression, indicated that the immune cells in the tumor were predominantly macrophages, and this was confirmed using immunohistochemical analysis. These findings indicate the possible use of checkpoint immunotherapy for the treatment of primary breast angiosarcoma.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão